SARS-CoV-2

Objective. Identification of clinical, laboratory, and instrumental factors more common in bacterial pneumonia compared to viral pneumonia, including COVID-19. Materials and Methods. This retrospective case-control study included hospitalized adults with communityacquired bacterial pneumonia and viral lung injury, including COVID-19. Patients were included taking into account age, gender, hospitalization department (general ward or ICU), and Charlson comorbidity index. Clinical, demographic, laboratory, and instrumental data on admission were studied. Unadjusted odds ratios (OR) were calculated using univariate logistic regression (for quantitative indicators) and contingency table analysis (for categorical indicators); adjusted OR were calculated using multivariate logistic regression.

Objective. To review and summarize literature data in studies of safety of the drug products used for the pathogenetic treatment of COVID-19. Materials and Methods. As the first stage of monitoring the drug’s safety, which are used in the treatment of COVID-19 in Russia, a systematic review of studies of the drug’s safety profiles was carried out: mefloquine, hydroxychloroquine, azithromycin, lopinavir/ritonavir, favipiravir, tocilizumab, olokizumab, baricitinib in the international databases Medline, PubMed, ClinicalTrials.

Mucormycosis is one of the most aggressive invasive mycoses. The mortality rate of patients with mucormycosis, depending on clinical form and background disease, varies from 30% to 100%. This article provides the first description of mucormycosis in …